treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice
Article Quality & Performance Metrics
Readership in this journal
PopularRanked #14 of 24 articles by views in basic and clinical neuroscience
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
Abstract
Imatinib (IM) treatment efficacy in 116 chronic myeloid leukemia (CML) patients in different studies was analyzed. Patient group was non‑selective with prospective enrollment. The study was based on real‑time patient’s register allows to treatment quality control due to clinical results. Cytogenetic response (CO), hematological data, and overall survival (OS) were used as criteria for the therapy efficacy. After 12 month of treatment in 46.4 % of CML patients in early chronic phase complete CO (CCO) was obtained, in 33.3 % — in the late chronic phase, and in 13.3 % — in accelerated phase. Deficit of daily imatinib dose and intervals in treatment schedule were made a negative influence on CO quality. The median of OS was 120 months.
| Reference Key |
golenkov2014onkogematologitreatment
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;A. K. Golenkov;L. L. Vysotskaya;E. V. Trifonova;T. A. Mitina;T. D. Lutskaya;E. V. Kataeva;G. A. Dudina;Yu. B. Chernykh;I. V. Buravtsova;A. N. Gurov;R. V. Gorenkov |
| Journal | basic and clinical neuroscience |
| Year | 2014 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.